These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 18383441)

  • 1. Developing tools for the safety specification in risk management plans: lessons learned from a pilot project.
    Cooper AJ; Lettis S; Chapman CL; Evans SJ; Waller PC; Shakir S; Payvandi N; Murray AB
    Pharmacoepidemiol Drug Saf; 2008 May; 17(5):445-54. PubMed ID: 18383441
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reports of hyperkalemia after publication of RALES--a pharmacovigilance study.
    Hauben M; Reich L; Gerrits CM
    Pharmacoepidemiol Drug Saf; 2006 Nov; 15(11):775-83. PubMed ID: 16804951
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Graphical approaches to the analysis of safety data from clinical trials.
    Amit O; Heiberger RM; Lane PW
    Pharm Stat; 2008; 7(1):20-35. PubMed ID: 17323410
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reevaluating the safety profile of pediatrics: a comparison of computerized adverse drug event surveillance and voluntary reporting in the pediatric environment.
    Ferranti J; Horvath MM; Cozart H; Whitehurst J; Eckstrand J
    Pediatrics; 2008 May; 121(5):e1201-7. PubMed ID: 18450863
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recommendations for safety planning, data collection, evaluation and reporting during drug, biologic and vaccine development: a report of the safety planning, evaluation, and reporting team.
    Crowe BJ; Xia HA; Berlin JA; Watson DJ; Shi H; Lin SL; Kuebler J; Schriver RC; Santanello NC; Rochester G; Porter JB; Oster M; Mehrotra DV; Li Z; King EC; Harpur ES; Hall DB
    Clin Trials; 2009 Oct; 6(5):430-40. PubMed ID: 19846894
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potential population-based electronic data sources for rapid pandemic influenza vaccine adverse event detection: a survey of health plans.
    Moore KM; Duddy A; Braun MM; Platt R; Brown JS
    Pharmacoepidemiol Drug Saf; 2008 Dec; 17(12):1137-41. PubMed ID: 18763248
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety reporting in randomized clinical trials - a need for improvement.
    Yazici Y
    Bull NYU Hosp Jt Dis; 2009; 67(2):209-10. PubMed ID: 19583556
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Some concerns about adverse event reporting in randomized clinical trials.
    Yazici Y
    Bull NYU Hosp Jt Dis; 2008; 66(2):143-5. PubMed ID: 18537786
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacovigilance-related topics at the level of the International Conference on Harmonisation (ICH).
    Bahri P; Tsintis P
    Pharmacoepidemiol Drug Saf; 2005 Jun; 14(6):377-87. PubMed ID: 15517542
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Implementation of an event reporting system in a transfusion medicine unit: a local experience.
    Usin MF; Ramesh P; Lopez CG
    Malays J Pathol; 2004 Jun; 26(1):43-8. PubMed ID: 16190106
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Risk and odds--how to calculate with events].
    Malmquist J
    Lakartidningen; 2002 Feb; 99(8):751-3, 756. PubMed ID: 11894612
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Monitoring and safety assessment in Phase I to III clinical trials.
    Fescharek R; Nicolay U; Arras-Reiter C
    Dev Biol Stand; 1998; 95():203-9. PubMed ID: 9855433
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biosimilars: pharmacovigilance and risk management.
    Zuñiga L; Calvo B
    Pharmacoepidemiol Drug Saf; 2010 Jul; 19(7):661-9. PubMed ID: 20583204
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Data mining for signals in spontaneous reporting databases: proceed with caution.
    Stephenson WP; Hauben M
    Pharmacoepidemiol Drug Saf; 2007 Apr; 16(4):359-65. PubMed ID: 17019675
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Risk management in the operation room. Results of a pilot project of interdisciplinary "incident reporting"].
    Horstmann R; Hofinger G; Mäder M; Gaidzik PW; Waleczek H
    Zentralbl Chir; 2006 Aug; 131(4):332-40. PubMed ID: 17004194
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lessons learned from independent central review.
    Ford R; Schwartz L; Dancey J; Dodd LE; Eisenhauer EA; Gwyther S; Rubinstein L; Sargent D; Shankar L; Therasse P; Verweij J
    Eur J Cancer; 2009 Jan; 45(2):268-74. PubMed ID: 19101138
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).
    Pergolizzi J; Böger RH; Budd K; Dahan A; Erdine S; Hans G; Kress HG; Langford R; Likar R; Raffa RB; Sacerdote P
    Pain Pract; 2008; 8(4):287-313. PubMed ID: 18503626
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Non-clinical Post-Marketing Commitments for newly licenced pharmaceuticals.
    Reeve LM
    Regul Toxicol Pharmacol; 2009 Nov; 55(2):181-7. PubMed ID: 19589365
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Decision support methods for the detection of adverse events in post-marketing data.
    Hauben M; Bate A
    Drug Discov Today; 2009 Apr; 14(7-8):343-57. PubMed ID: 19187799
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Testing for adverse reactions using prescription event monitoring.
    Andrew JE; Prescott P; Smith TM; Inman WH; Kubota K
    Stat Med; 1996 May; 15(10):987-1002. PubMed ID: 8783437
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.